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Introduction
Lung cancer is the leading cause of cancer death in
Taiwan, and Taipei Veterans General Hospital is the
leading hospital in the diagnosis and treatment of lung
cancer in Taiwan, for both civilians and veterans. Lung
cancer is also the major cause of cancer death in North
America and is even more common among veterans
there.1
A retrospective review of 12 original research papers
and meta-analyses explored whether patients’ socio-
economic status influenced doctor-patient communi-
cation, and the results showed that patients from higher
social classes communicated more actively and showed
more affective expressiveness, eliciting more informa-
tion from their doctor. In contrast, patients from lower
social classes were often disadvantaged because of the
doctor’s misperception of their desire and need for infor-
mation, and their ability to take part in the care process.
More effective communication could be established by
both doctors and patients through doctors’ awareness of
the contextual communicative differences, and by em-
powering patients to express concerns and preferences.2
Veterans affairs is an important issue in Taiwan since
the Kuomintang (KMT) brought about 500,000–
600,000 soldiers from China to Taiwan after their defeat
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by the Chinese Communist Party army and retreat to
Taiwan in 1949. In addition, they continued to enlist
soldiers for decades after arriving in Taiwan, to balance
forces across the Taiwan Strait. The army in Taiwan
supplied discounted or free cigarettes to the soldiers
during this period, with the result that many veterans
had smoking-related diseases, including lung cancer.
However, the health care system for veterans, and their
families, in Taiwan was especially well-designed and
accounted for a major part of the budget for veterans
affairs in Taiwan, with the result that veterans did not
have to pay health insurance, and they can visit hospitals
and outpatient clinics free of charge. Thus, the socio-
economic status of veterans in Taiwan did not have an
effect on their seeking medical care.
A population-based study of lung cancer in Penn-
sylvania, comparing veteran and civilian populations,
was published recently.1 The median survival was 6.3
months for veteran patients and 7.9 months for patients
in the rest of the state, and the 5-year overall survival
rate was 12% for veteran patients and 15% for patients
in the rest of the state. The authors concluded that
the overall survival of veterans with lung cancer in
Pennsylvania was inferior to that of patients in the
remainder of the state. They suggested further inves-
tigations to determine whether this disparity was caused
by differences in socioeconomic status or comorbidi-
ties, or whether there were systematic differences in the
diagnosis, staging, or treatment of lung cancer between
veteran and civilian patients. The present study was
undertaken to determine whether or not there exists a
difference in the clinical characteristics, marital status,
staging, treatment, and survival between Chinese vet-
erans and civilians with lung cancer, especially non-
small-cell lung cancer (NSCLC).
Methods
We retrospectively reviewed the medical records and
computer files of our lung cancer patients diagnosed
between 1996 and 2000. Only those patients who
had a histocytologic diagnosis of lung cancer were in-
cluded in the present study. Clinical staging was per-
formed with chest computed tomography (CT) scan
(including liver and adrenal glands), brain CT scan, and
whole-body bone scan examinations. Staging was done
according to the TNM staging criteria revised in 1997.3
Marital status (single, married, widowed/divorced) was
recorded based on the patients’ reports.
For the analysis, survival was measured from the
diagnosis of lung cancer until the date of death or last
follow-up. The Kaplan-Meier method with a log-rank
test was used for univariate survival analysis (α = 0.05).
The Cox regression test, including veteran or civilian,
age (≤ 65 or > 65 years) and sex, was used for multi-
variate survival analysis of all lung cancer and NSCLC
patients. Two-sided Pearson’s χ2 test was used for com-
parison between clinical characteristics or treatment
modality. The SPSS (Statistical Package for the Social
Sciences) statistical program was used.
Results
During this period, 3,727 patients with lung cancers
were diagnosed, including 3,312 patients with NSCLC
(88.9%) and 415 with SCLC (11.1%). Of the 3,312
NSCLC patients, 801 (24.2%) were female, and of the
415 SCLC patients, 38 (9.2%) were female (p <0.001).
Among the patients with NSCLC, adenocarcinoma
accounted for 1,743 (52.6%) cases, and squamous cell
carcinoma for 988 (29.8%) cases; the remaining 581
(17.5%) cases were type unspecified NSCLC. In the
staging of NSCLC, 500 (15.1%) patients were stage
I, 162 (4.9%) patients were stage II, 914 (27.6%)
patients were stage III, 1,426 (43.1%) patients were
stage IV, and the remaining 310 (9.4%) patients had
incomplete staging.
Among the 3,727 lung cancer patients, 2,386 were
civilians and the remaining 1,341 were veterans. Kaplan-
Meier survival analysis of all lung cancers showed that
civilians had better survival than veterans (median, 12
months vs. 8 months, p<0.001) (Figure 1). The 1-year,
3-year and 5-year survival rates were 48.5%, 19.2%
and 12.4% in civilians, and 36.1%, 13.8% and 8.9% 
in veterans, respectively. Median survival of veterans
with NSCLC was 9 months, while it was 13 months
in civilians (p < 0.001; Figure 2). The 1-year, 3-year
and 5-year survival rates were 50%, 20.5% and 13.4%
in civilians, and 38.7%, 15.1% and 9.6% in veterans,
respectively. Median survival of civilians with SCLC
(n = 229; median, 13 months) was longer than that for
veterans with SCLC (n = 186; median, 9 months), but
without statistical significance (p = 0.078).
Among 1,155 veterans with NSCLC, only 1,027
(88.9%) patients had complete staging. Similarly, 1,975
of 2,157 (91.6%) civilians had complete staging. When
survival analysis was performed according to staging
status, median survival time was better for civilians than
veterans in stage I NSCLC patients (62 months vs. 52
months, p = 0.093). The 5-year survival rate for stage I
NSCLC was 50.7% in civilians and 43% in veterans.
The 5-year survival rates for stage II, III and IV
NSCLC were 26.8%, 10.4% and 2.3% in civilians and
17.2%, 5.4% and 0.9% in veterans, respectively. Median
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survival was significantly better for civilian patients than
veterans, regardless of stage II, III or IV (Table 1).
When marital status was considered, civilian lung
cancer patients who were single (n = 139; median, 
8 months) had better survival than veterans who were
single (n = 290; median, 5 months) (p = 0.01; Figure
3). This survival difference was also significant between
civilians who were married (n = 2,048; median, 12
months) and veterans who were married (n = 947;
median, 9 months) (p < 0.001; Figure 4). However,
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Figure 1. Overall survival curve of 3,727 lung cancer patients diagnosed between 1996 and 2000. The median survival time was 
12 months in civilians and 8 months in veterans (p < 0.001). The 1-year, 3-year and 5-year survival rates were 48.5%, 19.2% and 12.4%

























Figure 2. Overall survival curve of 3,312 non-small-cell lung cancer patients diagnosed between 1996 and 2000. The median survival
time was 13 months in civilians and 9 months in veterans (p < 0.001). The 1-year, 3-year and 5-year survival rates were 50%, 20.5%
and 13.4% in civilians, and 38.7%, 15.1% and 9.6% in veterans, respectively.
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there was no survival difference between civilians (n =
150; median, 8 months) and veterans (n = 62; median,
5 months) who were widowed or divorced (p =0.144).
Among 1,155 veterans with NSCLC, the marital
status of 1,121 veterans was known, including 247
single, 816 married, and 58 widowed or divorced. The
veterans who were married had better survival than
those who were single, widowed or divorced, with a
median survival difference of at least 5 months (p <
0.001; Figure 5). The 1-year, 3-year and 5-year survival
rates for veterans who were married were 42.6%, 17.3%
and 11.5%, for those who were single were 29.7%, 7.4%
and 3.5%, and for those who were widowed or divorced
were 24.1%, 15.5% and 9.9%, respectively. Marital sta-
tus also had a similar impact on the survival status of
veterans with stage IV NSCLC (p < 0.001; Figure 6).
Median survival was 10 months, 5 months and 4
months, and 1-year survival rates were 27.2%, 14.3%
and 3.8% for veterans with stage IV NSCLC who
were married (n = 320), single (n = 106) and widowed
or divorced (n = 26), respectively. Those patients who
had stage IV NSCLC and who were married received
Table 1. Survival status of non-small-cell lung cancer patients according to staging
Survival
p
Median (mo) 1-year (%) 2-year (%) 3-year (%) 5-year (%)
Stage I 0.093
C (n = 335) 62 89.3 75.5 64.5 50.7
V (n = 165) 52 81.8 70.9 58.6 43.0
Stage II 0.029
C (n = 98) 21 60.6 43.8 36.5 26.8
V (n = 64) 11 46.9 32.8 23.4 17.2
Stage III < 0.001
C (n = 582) 13 54.7 26.4 18.3 10.4
V (n = 332) 10 38.0 20.5 9.9 5.4
Stage IV < 0.001
C (n = 960) 8 32.8 12.9 6.0 2.3
V (n = 466) 5 22.8 7.5 3.2 0.9
C = civilians; V = veterans.
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Figure 3. Overall survival curve of 429 lung cancer patients who were single. The median survival time was 8 months in civilians
(n = 139) and 5 months in veterans (n = 290) (p = 0.01). The 1-year, 3-year and 5-year survival rates were 34.1%, 14.9% and 8.9% in
civilians, and 27%, 7% and 3.7% in veterans, respectively.
J Chin Med Assoc • June 2008 • Vol 71 • No 6290
Y.M. Chen, et al
chemotherapy more frequently (48.4%), followed by
those who were single (31.1%), and those who were
widowed or divorced (23.1%) (p=0.001). However, no
significant difference in survival was found between
these 3 groups of patients (median survival, 3 months,
3 months, and 2 months, respectively, for married,
single, and widowed or divorced; p = 0.374). The 
1-year survival rates were 36.1%, 34.5%, and 16.7%,
respectively, for married, single, and widowed or di-
vorced patients. In contrast, 165 married, 73 single,
























Figure 4. Overall survival curve of 2,995 lung cancer patients who were married. The median survival time was 12 months in civilians
(n = 2,048) and 9 months in veterans (n = 947) (p < 0.001). The 1-year, 3-year and 5-year survival rates were 49.9%, 19.8% and 13% 
in civilians, and 39.8%, 15.7% and 10.4% in veterans, respectively.
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Figure 5. Overall survival curve of 1,121 veterans with non-small-cell lung cancer whose marital status was known. The median survival
was 10 months, 5 months and 4 months for those who were married, single and widowed or divorced, respectively (p < 0.001). The 1-year,
3-year and 5-year survival rates for veterans who were married were 42.6%, 17.3% and 11.5%. The corresponding rates were 29.7%,
7.4% and 3.5% for those who were single, and 24.1%, 15.5% and 9.9% for those who were widowed or divorced.
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and 20 widowed or divorced veterans received the
best supportive care only. There was a significant dif-
ference in survival in these patients who received sup-
portive care only, and the best survival was found in
those who were married (median survival, 3 months,
2 months, and 3 months, respectively, for married, sin-
gle, and widowed or divorced; p = 0.002). The 1-year
survival rates were 18.8%, 5.5%, and 0%, respectively,
for married, single, and widowed or divorced.
In married veterans, surgery was the primary treat-
ment modality in 211 of 816 patients (25.9%); 40 of
193 single (20.7%), and 14 of 68 (20.6%) widowed 
or divorced veterans also received surgery (p = 0.241).
Chemotherapy was the primary treatment modality in
303 of 816 married veterans (37.1%); 78 of 193 sin-
gle (40.4%), and 13 of 68 (19.1%) widowed or divorced
veterans also received chemotherapy (p=0.006). In con-
trast, veterans who were single (35.8%) and those who
were widowed or divorced (29.4%) received support-
ive care only more frequently than married veterans
(21.7%) (p < 0.001).
A comparison of treatment modality between veter-
ans and civilians based on staging showed that surgery
was the main treatment modality in both stage I and
II civilians and veterans. However, a greater propor-
tion of veterans in stage II and III than civilians at 
the same stage underwent radiotherapy, and there was
a statistically significant difference in stage III patients
(p < 0.001). There was no statistical difference in the
treatment modality of stage IV civilians and veterans
(Table 2).
When considering male patients alone, male civilian
lung cancer patients (n = 1,557; median, 11 months)
had better survival than male veteran patients (n =
1,331; median, 8 months) (p < 0.001). Among male
patients with NSCLC, civilians (n = 1,364; median,
11 months) had better survival than veterans (n=1,147;
median, 9 months) (p < 0.001). Among male patients
with stage IV NSCLC, civilians (n = 565; median, 
6 months) had better survival than veterans (n = 462;
median, 5 months) (p = 0.004). Importantly, there was
no survival difference between male civilians (n = 256;
median, 8 months) and veterans (n = 199; median, 
8 months) with stage IV NSCLC who received chemo-
therapy (p = 0.255).
Age is another important factor. Since the majority
of veterans who retreated from China were older than
65 years in 1996, we classified lung cancer patients
into those 65 years old or younger and those older
than 65 years. We found that survival was poorer for
elderly veterans (n = 1,261) with lung cancer than for
elderly civilians (n = 1,306) (median, 8 months vs. 10
months, p =0.009), and for elderly veterans (n =1,090)
with NSCLC compared to elderly civilians (n = 1,153)
(median, 8 months vs. 10 months, p = 0.019). In con-
trast, no survival difference was found between civilians
and veterans with lung cancer, or NSCLC patients aged
65 years or younger (data not shown).
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Figure 6. Overall survival curve of 452 veterans with stage IV non-small-cell lung cancer (NSCLC) whose marital status was known. The
median survival was 10 months, 5 months and 4 months, and 1-year survival was 27.2%, 14.3% and 3.8% for veterans with stage IV
NSCLC who were married, single and widowed or divorced, respectively (p < 0.001).
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Multivariate Cox-regression survival analysis, includ-
ing civilian or veteran, sex and age (≤ 65 years or > 65
years), showed that only sex and age were independ-
ent risk factors for mortality, with hazard ratios of 1.194
and 0.762, respectively. Sex and age were also inde-
pendent risk factors for mortality, with hazard ratios of
1.145 and 0.765, respectively, for NSCLC (Table 3).
Discussion
It has been reported that patients who have racial dif-
ferences and discordant interactions with their doctors
do less to prompt doctors for information, and doctors
in turn provide less information to these patients.4 It
was also noted that black patients may have lower trust
in their physicians, in part because of poorer physician-
patient communication, when compared with white
patients.5 Whether or not such a difference exists in
Taiwan, where veterans and civilians are all of Chinese
ethnicity, is unknown. However, veterans, especially
those who retreated from China, are a specific subpop-
ulation in Taiwan with a relatively lower educational
level, and many of these patients who retired as rank-
and-file soldier or non-commissioned officer are in
lower socioeconomic levels. In contrast, the second gen-
eration of veterans who retired as officers in Taiwan is
generally well-educated and in higher socioeconomic
levels. The communication between the former group
of patients (retired as rank-and-file soldier or non-
commissioned officer) and their families is less inform-
ative or less compliant than that between the latter
group (retired as officers) and their families.
Surgical treatment was given to the majority of
patients (83%), both civilian and veteran, with stage I
NSCLC. Veterans received less surgical treatment in
stage II (56% vs. 64%) and stage III (16% vs. 26%)
NSCLC, compared to civilians in the same stage, with
radiotherapy more common for those veterans who did
not receive surgical intervention, suggesting that a more
conservative treatment was given to some of these
populations (p < 0.001 in stage III patients; Table 2).
The most likely reason is that the majority of veteran
patients were older than the civilian patients, and that
chronic obstructive pulmonary disease with poor pul-
monary and even cardiovascular function was more
common in veterans.6 The reason for this is that each
soldier in Taiwan received at least 20 packs of ciga-
rettes free of charge or at a discounted price every month
from the government for decades after the KMT re-
treated from China to Taiwan, thus leading many sol-
diers, and later veterans, to develop and sustain the
Table 2. Primary treatment modality of 3,002 non-small-cell lung cancer patients who had complete staging information*
Stage Surgery Radiotherapy Chemotherapy Supportive care p†
I 0.543
Civilian 279 (83.3) 22 (6.6) 9 (2.7) 25 (7.5)
Veteran 137 (83) 15 (9.1) 5 (3) 8 (4.8)
II 0.279
Civilian 63 (64.3) 10 (10.2) 6 (6.1) 19 (19.4)
Veteran 36 (56.3) 9 (14.1) 9 (14.1) 10 (15.6)
III < 0.001
Civilian 154 (26.5) 80 (13.7) 244 (41.9) 104 (17.9)
Veteran 54 (16.3) 72 (21.7) 151 (45.5) 55 (16.6)
IV 0.051
Civilian 84 (8.8) 174 (18.1) 452 (47.1) 250 (26)
Veteran 29 (6.2) 88 (18.9) 200 (42.9) 149 (32)
*Data presented as n (%); †Pearson’s 2-sided c2 test comparing treatment modality between civilians and veterans.
Table 3. Multivariate survival analysis of patients with lung cancer
or non-small-cell lung cancer (NSCLC)
HR 95% CI p
Lung cancer
Veteran vs. civilian 1.058 0.976–1.146 0.173
Male vs. female 1.194 1.092–1.307 < 0.001
Age ≤ 65 yr vs. 0.762 0.703–0.827 < 0.001
> 65 yr
NSCLC
Veteran vs. civilian 1.061 0.972–1.157 0.183
Male vs. female 1.145 1.043–1.257 0.005
Age ≤ 65 yr vs. 0.765 0.072–0.834 < 0.001
> 65 yr
HR = hazard ratio; CI = confidence interval.
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habit of smoking. This free-of-charge cigarette policy in
the army was stopped more than 10 years ago. Another
possibility is that civilians tend to receive treatment more
aggressively than veterans, since more civilians under-
went chemotherapy and more veterans received sup-
portive care alone in stage IV NSCLC, with borderline
statistical significance (p = 0.051; Table 2).
The majority of veterans who retreated from China
were older than 65 years in 1996. We found that eld-
erly veterans with lung cancer or NSCLC had poorer
survival than elderly civilians. The prevalence of comor-
bidities such as chronic obstructive pulmonary disease
and cardiovascular disease that was related to smoking
was higher in elderly veterans than in civilians, due to
the higher prevalence rate of smoking in veteran pop-
ulations. However, there was no survival difference
between the younger civilians and veterans who suf-
fered from lung cancer or NSCLC, and the majority
of these younger veterans joined the military after the
KMT had retreated to Taiwan. More importantly, there
was no survival difference in male patients with stage
IV NSCLC who received chemotherapy among civil-
ians and veterans (p = 0.255), with the same median
survival of 8 months and 1-year survival rates of 38.6%
in civilians and 34.4% in veterans. This meant that
there was a similar chemotherapy treatment effect on
cancer patients regardless of whether they were a civil-
ian or veteran once the patient had been judged to be
appropriate for chemotherapy;7–10 the support system
and medical care for veterans is rather robust in Taiwan.
In addition, multivariate survival analysis showed that
veteran standing was not a significant prognostic factor
when age and sex were considered together, suggesting
that both civilians and veterans had similar survival
when the factors of age and sex were excluded.
Veterans with stage IV NSCLC who were married
received chemotherapy more frequently than those who
were single, widowed or divorced. The 1-year survival
rate was significantly better for veterans with stage IV
NSCLC who received chemotherapy than for those
who did not receive chemotherapy, regardless of marital
status. Survival status was better for married veterans,
even when they received supportive care only, when
compared with single, widowed or divorced veterans.
Thus, marital status and family are other important
sources of support, especially psychological support,
for veteran patients with lung cancer.
In conclusion, this is the largest study so far dis-
cussing veteran patients with lung cancer who mainly
came from China and stayed in Taiwan. The poor sur-
vival of these veterans is due to age and sex rather than
to their standing as veterans.
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